Seasoned industry executive brings proven leadership to support commercial scale of IsoPSA® Assay & platform expansion
Cleveland Diagnostics, Inc., a leading commercial-stage precision oncology company, announced that Jack Kenny has been appointed Chairman of the Board of Directors. Kenny joins the company at a key moment as Cleveland Diagnostics ramps up commercial growth following the recent FDA clearance of its IsoPSA IVD Assay and continues to advance its broader IsoClear platform.
Health Technology Insights: Integrity Health Cuts Costs 16 Percentage Using Lightbeam Health Platform
Kenny brings over 30 years of experience in operational, commercial, and board leadership across the diagnostics and life sciences sectors. He has extensive expertise in in vitro diagnostics, molecular testing, and laboratory services. Most recently, he served as Chief Executive Officer of Meridian Bioscience and has held senior roles at Siemens Healthcare, Becton Dickinson Diagnostics, Danaher, and Quest Diagnostics. Kenny has also served on boards of both public and private companies throughout his career.
Health Technology Insights: PDS Health Partners With Pearl for Enterprise AI Integration
“Cleveland Diagnostics is entering a critical phase of growth,” said Kenny. “I am excited to join the board at this time and work closely with the leadership team to scale the business, expand access to IsoPSA, and support a platform with the potential to impact areas beyond prostate cancer.”
Recent executive appointments further strengthen the company as it enters 2026. Michael Iskra was named Chief Executive Officer earlier this year and brings extensive experience in global diagnostics commercialization. Meanwhile, cofounding CEO Dr. Arnon Chait has transitioned to Chief Innovation Officer to focus on advancing the IsoClear platform into additional cancer indications.
“Jack’s experience in guiding companies through important growth milestones makes him an ideal chairman for Cleveland Diagnostics,” said CEO Michael Iskra. “With FDA approval secured, a clear commercial strategy in motion, and Arnon driving innovation, our leadership team is aligned to make 2026 a transformative year for the company.”
Health Technology Insights: John Snow Labs Achieves Pacific AI Certification for Healthcare
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
